查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108393

腦膜炎雙球菌疫苗市場分析及至2035年預測：類型、產品、技術、應用、最終用戶、給藥方法、研發階段

Meningococcal Vaccines Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球腦膜炎雙球菌疫苗市場預計將從2025年的41億美元成長到2035年的89億美元，複合年成長率（CAGR）為7.9%。隨著各國政府加強常規免疫規劃和集體爆發防治，全球腦膜炎雙球菌疫苗市場持續擴張。世界衛生組織（世衛組織）指出，雖然接種疫苗族群的發生率有所下降，但腦膜炎雙球菌病菌感染仍然是一個重要的公共衛生問題，推動了疫苗的持續採購。在主導，非洲全國推廣接種A群腦膜炎雙球菌結合疫苗，已為數億人接種，顯著減少了疫情爆發。產業評估顯示，在B群腦膜炎雙球菌疫苗普及和新一代多價疫苗研發的推動下，2025年全球市場規模將超過40億美元，預計在整個預測期內複合年成長率將超過7%。

多醣體疫苗集體爆發控制和短期免疫，但其有限的免疫記憶限制了其長期保護作用。另一方面，結合疫苗因其卓越的免疫反應、群體免疫效應以及對各年齡層的長期保護作用，已成為臨床實踐的主流，並構成國家免疫規劃的核心。聯合疫苗整合了對多種腦膜炎球菌血清型的保護，提高了免疫效率，同時減少了就診次數和接種成本。結合技術的持續進步、血清群覆蓋範圍的擴大以及政府支持的免疫規劃的增加，預計將推動已開發經濟體和新興經濟體醫療保健系統的持續創新和市場擴張。

市場區隔
類型 結合疫苗、多醣體疫苗、莢膜下疫苗及其他
產品 MenACWY、MenB、MenC、MenA、MenAC、MenABCWY 等。
科技 重組DNA技術、細胞培養技術及其他
目的 兒童、成人、旅行者、相關人員及其他人員
最終用戶 醫院、診所、學術和研究機構以及其他
給藥方法 注射劑、鼻噴霧及其他
發展階段 臨床前研究、臨床試驗、商業化等。

由於其對四種具有重要臨床意義的血清群具有廣泛的保護效力，且被廣泛納入青少年免疫接種計劃，MenACWY疫苗佔了最大的產品類型。隨著各國為因應B群集體爆發所提出的建議，MenB疫苗的使用率也不斷提高。 MenC和MenA疫苗持續滿足特定地區的免疫接種需求，尤其是在疾病高發生率地區。 MenAC製劑支持有針對性的免疫接種工作，而MenACWY-CRM和MenACWY-TT結合疫苗則透過不同的載體蛋白增強了免疫抗原性。產品創新日益著重於擴大血清群保護範圍、延長免疫持續時間和簡化免疫接種程序，從而支持長期的商業性成長。

區域概覽

北美憑藉其完善的免疫基礎設施、有利的保險報銷機制和健全的公共衛生監測體系，在腦膜炎球菌疫苗市場佔有舉足輕重的佔有率。該地區受益於青少年常規免疫接種的推薦、廣泛的醫療保健服務以及完善的採購體系，這些都支撐著穩定的疫苗需求。領先的製藥企業在全部區域擁有強大的研發、生產和商業化能力，加速了產品創新和監管批准。對先進的結合疫苗和多價疫苗的持續投資，以及學校、學院和軍事相關人員的機構免疫接種要求，進一步鞏固了市場的穩定成長和持續的商業性機會。

亞太地區正經歷著顯著的市場發展，這主要得益於疫苗接種率的提高、醫療保健支出的增加以及公眾對疫苗可預防疾病認知的不斷增強。各國政府正持續加強國家免疫規劃，同時發展低溫運輸基礎設施並改善醫療保健服務的可近性。人口成長、都市化以及疾病監測系統的完善進一步加速了疫苗在兒童和青少年中的分發。國際夥伴關係、對國內疫苗生產的投資以及監管現代化正在提升該地區的全部區域供給能力。預計區域生物技術公司的參與度提高以及公共衛生機構採購量的增加將推動亞太地區疫苗需求的持續成長和產業的長期發展。

主要趨勢和促進因素

疫苗研發的技術進步

由於疫苗研發技術的進步，腦膜炎雙球菌疫苗市場正經歷顯著成長。結合疫苗和重組DNA技術等創新成果提高了腦膜炎雙球菌疫苗的有效性和安全性。這些技術使得生產能夠更廣泛地預防多種腦膜炎奈瑟菌血清群（腦膜炎雙球菌疾病的病原體）感染的疫苗成為可能。因此，這些先進疫苗正被擴大納入全球免疫規劃，從而推動了市場擴張。

政府的疫苗接種政策正在加速市場成長。

政府對常規免疫和集體爆發預防的重視程度不斷提高，仍是市場擴張的主要驅動力。大眾對侵襲性腦膜炎雙球菌病菌感染的認知不斷增強，監測系統不斷完善，世界衛生組織的建議也正在推動嬰幼兒、青少年、旅行者和高風險族群的疫苗接種率上升。公共採購舉措、學校免疫接種計畫以及不斷擴大的醫療衛生基礎設施持續刺激需求，同時也為疫苗研發、生產和分銷方面的長期投資提供了支持。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 結合疫苗
    • 多醣體疫苗
    • 皮下疫苗
    • 其他
  • 市場規模及預測：依產品分類
    • MenACWY
    • MenB
    • MenC
    • MenA
    • MenAC
    • MenABCWY
    • 其他
  • 市場規模及預測：依技術分類
    • 重組DNA技術
    • 細胞培養技術
    • 其他
  • 市場規模及預測：依應用領域分類
    • 兒童
    • 成人
    • 遊客
    • 軍事相關人員
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 學術和研究機構
    • 其他
  • 市場規模及預測：按管理方法
    • 注射
    • 鼻噴霧
    • 其他
  • 市場規模及預測：依發展階段分類
    • 臨床前
    • 臨床檢測
    • 商業化
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Merck
  • Novartis
  • Bharat BIoTech
  • Serum Institute of India
  • Biomed
  • Janssen Pharmaceuticals
  • Emergent BioSolutions
  • CSL Limited
  • Biological E
  • Hualan Biological Engineering
  • Walvax BIoTechnology
  • Chongqing Zhifei Biological Products
  • Panacea BIoTec
  • Mitsubishi Tanabe Pharma
  • Dynavax Technologies
  • Valneva
  • Incepta Vaccine

第9章 關於我們

簡介目錄
Product Code: GIS25745

The global Meningococcal Vaccines Market is projected to grow from $4.1 billion in 2025 to $8.9 billion by 2035, at a compound annual growth rate (CAGR) of 7.9%. The global meningococcal vaccines market continues expanding as governments strengthen routine immunization programs and outbreak preparedness strategies. According to the World Health Organization (WHO), meningococcal disease remains a significant public health concern despite declining incidence in vaccinated populations, encouraging sustained vaccine procurement. The WHO-led rollout of meningococcal A conjugate vaccines across Africa has vaccinated hundreds of millions of individuals, substantially reducing epidemic occurrence. Industry assessments indicate the global market is valued at over USD 4 billion in 2025, with projected compound annual growth exceeding 7% through the forecast period, supported by expanding MenB adoption and next-generation multivalent vaccine development.

Polysaccharide vaccines have historically served outbreak control and short-term immunization but offer limited immunological memory, restricting long-term protection. Conjugate vaccines dominate clinical practice due to superior immune response, herd immunity benefits, and prolonged protection across different age groups, making them central to national immunization schedules. Combination vaccines integrate protection against multiple meningococcal serogroups, improving vaccination efficiency while reducing healthcare visits and administration costs. Continued advancements in conjugation technologies, broader serogroup coverage, and increasing government-supported immunization programs are expected to sustain innovation and market expansion across developed and emerging healthcare systems.

Market Segmentation
TypeConjugate Vaccines, Polysaccharide Vaccines, Subcapsular Vaccines, Others
ProductMenACWY, MenB, MenC, MenA, MenAC, MenABCWY, Others
TechnologyRecombinant DNA Technology, Cell Culture Technology, Others
ApplicationPediatrics, Adults, Travelers, Military Personnel, Others
End UserHospitals, Clinics, Academic and Research Institutes, Others
ModeInjection, Nasal Spray, Others
StagePreclinical, Clinical Trials, Commercialized, Others

MenACWY vaccines represent the largest product category owing to broad protection against four clinically significant serogroups and widespread inclusion in adolescent immunization schedules. MenB vaccines are witnessing increasing adoption following recommendations in countries addressing serogroup B outbreaks. MenC and MenA vaccines continue serving region-specific immunization requirements, particularly where disease prevalence remains concentrated. MenAC formulations support targeted vaccination initiatives, while MenACWY-CRM and MenACWY-TT conjugate products provide enhanced immunogenicity through different carrier proteins. Product innovation increasingly focuses on expanded serogroup protection, improved durability, and simplified vaccination schedules supporting long-term commercial growth.

Geographical Overview

North America maintains a substantial share of the meningococcal vaccines market through comprehensive immunization infrastructure, favorable reimbursement systems, and strong public health surveillance. The region benefits from routine adolescent vaccination recommendations, extensive healthcare access, and established procurement frameworks supporting consistent vaccine demand. Leading pharmaceutical manufacturers maintain significant research, manufacturing, and commercialization capabilities across the region, accelerating product innovation and regulatory approvals. Continuous investments in advanced conjugate and multivalent vaccines, combined with institutional vaccination requirements for schools, colleges, and military personnel, reinforce stable market expansion and sustained commercial opportunities.

Asia-Pacific demonstrates significant market development supported by expanding immunization coverage, rising healthcare expenditure, and increasing awareness of vaccine-preventable diseases. Governments continue strengthening national vaccination programs while improving cold-chain infrastructure and healthcare accessibility. Population growth, urbanization, and enhanced disease surveillance encourage broader vaccine adoption across pediatric and adolescent populations. International partnerships, domestic vaccine manufacturing investments, and regulatory modernization are improving supply capabilities throughout the region. Growing participation from regional biotechnology companies and increasing procurement by public health agencies position Asia-Pacific for sustained demand and long-term industry development.

Key Trends and Drivers

Technological Advancements in Vaccine Development:

The meningococcal vaccines market is experiencing significant growth due to technological advancements in vaccine development. Innovations such as conjugate vaccines and recombinant DNA technology have enhanced the efficacy and safety profiles of meningococcal vaccines. These technologies enable the production of vaccines that provide broader protection against multiple serogroups of Neisseria meningitidis, the bacteria responsible for meningococcal disease. As a result, there is a growing adoption of these advanced vaccines in immunization programs worldwide, contributing to market expansion.

Government Vaccination Policies Accelerate Market Growth:

Growing government commitment toward routine immunization and outbreak prevention remains the primary driver of market expansion. Rising awareness of invasive meningococcal disease, strengthened surveillance systems, and recommendations from global health organizations encourage broader vaccine coverage among infants, adolescents, travelers, and high-risk populations. Public procurement initiatives, school-entry vaccination policies, and expanding healthcare infrastructure continue stimulating demand while supporting long-term investments in vaccine research, production, and distribution.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Mode
  • 2.7 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Conjugate Vaccines
    • 4.1.2 Polysaccharide Vaccines
    • 4.1.3 Subcapsular Vaccines
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 MenACWY
    • 4.2.2 MenB
    • 4.2.3 MenC
    • 4.2.4 MenA
    • 4.2.5 MenAC
    • 4.2.6 MenABCWY
    • 4.2.7 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant DNA Technology
    • 4.3.2 Cell Culture Technology
    • 4.3.3 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Pediatrics
    • 4.4.2 Adults
    • 4.4.3 Travelers
    • 4.4.4 Military Personnel
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Academic and Research Institutes
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Mode (2020-2035)
    • 4.6.1 Injection
    • 4.6.2 Nasal Spray
    • 4.6.3 Others
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Preclinical
    • 4.7.2 Clinical Trials
    • 4.7.3 Commercialized
    • 4.7.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Mode
      • 5.2.1.7 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Mode
      • 5.2.2.7 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Mode
      • 5.2.3.7 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Mode
      • 5.3.1.7 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Mode
      • 5.3.2.7 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Mode
      • 5.3.3.7 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Mode
      • 5.4.1.7 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Mode
      • 5.4.2.7 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Mode
      • 5.4.3.7 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Mode
      • 5.4.4.7 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Mode
      • 5.4.5.7 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Mode
      • 5.4.6.7 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Mode
      • 5.4.7.7 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Mode
      • 5.5.1.7 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Mode
      • 5.5.2.7 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Mode
      • 5.5.3.7 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Mode
      • 5.5.4.7 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Mode
      • 5.5.5.7 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Mode
      • 5.5.6.7 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Mode
      • 5.6.1.7 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Mode
      • 5.6.2.7 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Mode
      • 5.6.3.7 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Mode
      • 5.6.4.7 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Mode
      • 5.6.5.7 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Pfizer
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 GlaxoSmithKline
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Sanofi
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Merck
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Novartis
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Bharat Biotech
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Serum Institute of India
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Biomed
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Janssen Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Emergent BioSolutions
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 CSL Limited
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Biological E
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Hualan Biological Engineering
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Walvax Biotechnology
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Chongqing Zhifei Biological Products
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Panacea Biotec
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Mitsubishi Tanabe Pharma
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Dynavax Technologies
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Valneva
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Incepta Vaccine
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us